Avenue TherapeuticsATXI +3.11%31 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates ATXI with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Avenue Therapeutics ranks worse than 57.73% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Avenue Therapeutics EBITDA Margin % Related Terms
Avenue Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Avenue Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATXI vs PTIX, EVFM, AGTX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Avenue Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics (ATXI) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Avenue Therapeutics and its competitors. According to the industry distribution chart, Avenue Therapeutics ranks #545 out of 944 companies in the Biotechnology industry, placing it in the top 57.7%.
Is Avenue Therapeutics' EBITDA Margin % too high?
Avenue Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Avenue Therapeutics ranks #545 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Avenue Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' EBITDA Margin % compare to PTIX and EVFM?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #545 out of 944 companies for EBITDA Margin %. This places Avenue Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Avenue Therapeutics and its competitors. Avenue Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Avenue Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
31GF Score
Get the complete analysis for ATXI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATXI has been successfully added to your 
